患有AML和IDH2-R172突变的患者对强化化疗诱导产生独特的初始反应
Meira Yisraeli Salman1, Alexander R Terry1, Andriy Derkach2
1Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Blood advances
|April 8, 2025
概括
患有急性髓性白血病 (AML) 和IDH2-R172突变的患者在化疗后表现出较慢的弹性减少. 尽管如此,结果仍然有利,表明定制的治疗策略可能对这一AML亚组有益.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 中期循环骨髓活检 (BMB) 对评估急性髓性白血病 (AML) 强化化疗 (IC) 后反应的有用性仍在争论中.
- 在基因定义的AML亚组中,反应动态可能会有所不同,但这往往被忽视.
研究的目的:
- 为了研究AML患者IDH2-R172突变 (R172-m) 到IC的反应动力学.
- 为了比较R172-m和IDH2-R140突变 (R140-m) AML之间的爆发减速动态.
主要方法:
- 对接受IC治疗的新诊断的IDH2突变AML患者进行了回顾性单中心分析.
- 雷声减振动态的比较和与患者结果的相关性.
主要成果:
- 与R140-m (p=0.017) 相比,R172-m患者的BMB爆破数量在周期中期显著增加 (70%与5%相比),爆破清除速度较慢 (≤5%爆破).
- 没有R172-m患者在周期中期达到≤5%的爆发,而R140-m患者的58%是如此.
- 尽管最初的爆发减缓速度较慢,但两组的整体存活率相似且有利.
结论:
- 具有IDH2-R172突变的AML在IC后表现出明显的缓慢爆裂减少模式,此前主要在急性前兆细胞白血病中观察到.
- 对R172-m AML.有必要明智地应用重新诱导策略.
- 建议对这些反应动态进行进一步的研究.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K